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Background: Flotillin-1 and flotillin-2 are two homologous and ubiquitously expressed proteins that are involved in
signal transduction and membrane trafficking. Recent studies have reported that flotillins promote breast cancer
progression, thus making them interesting targets for breast cancer treatment. In the present study, we have investigated
the underlying molecular mechanisms of flotillins in breast cancer.
Methods: Human adenocarcinoma MCF7 breast cancer cells were stably depleted of flotillins by means of lentivirus
mediated short hairpin RNAs. Western blotting, immunofluorescence and quantitative real-time PCR were used to analyze
the expression of proteins of the epidermal growth factor receptor (EGFR) family. Western blotting was used to
investigate the effect of EGFR stimulation or inhibition as well as phosphatidylinositol 3-kinase (PI3K) inhibition
on mitogen activated protein kinase (MAPK) signaling. Rescue experiments were performed by stable transfection of
RNA intereference resistant flotillin proteins.
Results: We here show that stable knockdown of flotillin-1 in MCF7 cells resulted in upregulation of EGFR mRNA and
protein expression and hyperactivation of MAPK signaling, whereas ErbB2 and ErbB3 expression were not affected.
Treatment of the flotillin knockdown cells with an EGFR inhibitor reduced the MAPK signaling, demonstrating that the
increased EGFR expression and activity is the cause of the increased signaling. Stable ectopic expression of flotillins in
the knockdown cells reduced the increased EGFR expression, demonstrating a direct causal relationship between
flotillin-1 expression and EGFR amount. Furthermore, the upregulation of EGFR was dependent on the PI3K signaling
pathway which is constitutively active in MCF7 cells, and PI3K inhibition resulted in reduced EGFR expression.
Conclusions: This study demonstrates that flotillins may not be suitable as cancer therapy targets in cells that carry
certain other oncogenic mutations such as PI3K activating mutations, as unexpected effects are prone to emerge upon
flotillin knockdown which may even facilitate cancer cell growth and proliferation.
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Each year, hundreds of thousands of women around the
world are diagnosed with breast cancer. Depending on
the tumor stage upon diagnosis and the subtype of the
cancer, the survival rates are highly variable. Although
many treatment options are available, the best therapy
depends on the molecular features of the tumor. For ex-
ample, the so-called triple-negative tumors that lack estro-
gen and progesterone receptors and do not exhibit
amplification/overexpression of the epidermal growth
factor receptor (EGFR) family member ErbB2/Her2 can-
not be treated with chemotherapeutic drugs that specific-
ally target these molecules. Thus, personalized medicine,
i.e. knowing the molecular signature of the tumor to
be treated, has become essential for optimal and effi-
cient treatment of cancers.
The phosphatidylinositol 3-kinase/protein kinase B (also
known as AKT) signaling mode is an important regulator
of cell survival, motility and growth for a review, see [1,2].
PI3 kinases (PI3K) can be activated by e.g. growth factor
signaling and mediate the activation of AKT, a protein
kinase with numerous substrates that include the mech-
anistic target of rapamycin (mTOR) and some mem-
bers of the Forkhead transcription factor family, e.g.
FOXO3 [3-6]. In line with its importance in cell sur-
vival, PI3K is frequently mutated in various tumors, es-
pecially in breast, gastric and colorectal cancers [7,8].
Most of the oncogenic mutations are found in the
PIK3CA gene (GenBank: NM_006218.2) that encodes
for the catalytic p110α subunit of PI3K. The most fre-
quently observed mutations in this protein in cancers
are the H107R substitution in the kinase domain and
E545K in the helical domain [8-10]. Both mutation result
in constitutive activation of PI3K/AKT signaling and con-
tribute to cellular transformation [11,12].
Flotillin-1 and flotillin-2 are highly conserved proteins
that are associated with specific lipid microdomains in
cellular membranes [for a review, see [13,14]. Flotillins
reside on the cytoplasmic face of membranes [15] and
exhibit a broad cell type and stimulus dependent cellular
localization. In many cells, flotillins are found at the
plasma membrane and endosomal structures, but they
have also been shown to localize to the nucleus, cell-
matrix adhesions, the Golgi and phagosomes [16-21].
Flotillins have been suggested to function in membrane
trafficking processes such as endocytosis and recycling,
in cell-matrix and cell-cell adhesion but also in receptor
tyrosine kinase signaling [17,19,20,22-31]. We have re-
cently shown that flotillin-1 is important for the proper
activation and clustering of the EGFR after ligand bind-
ing. Furthermore, downstream signaling from EGFR
towards the mitogen activated protein kinase (MAPK)
cascade requires flotillin-1 which can directly interact
with the proteins of the MAPK cascade and functionsas a novel MAPK scaffolding protein [16], reviewed in
[32]. During EGFR signaling, flotillins are Tyr phos-
phorylated by the Src family kinases and become endo-
cytosed from the plasma membrane into endosomes
[17,27]. However, they do not appear to be involved in
EGFR endocytosis [16].
Several studies have shown that flotillins are important
regulators of cellular signaling and their overexpression
is associated with various types of cancers, such as mel-
anoma, breast cancer, head and neck cancer and gastric
cancer [29,33-37]. Importantly, flotillin overexpression
was shown to correlate with poor prognosis and shorter
survival of the patients. First findings suggesting a po-
tential connection of flotillins with cancer were pub-
lished almost a decade ago when Hazarika et al. showed
that flotillin-2 overexpression is associated with meta-
static potential in melanoma [34]. In gastric cancer,
flotillin-2 levels show a correlation with Her2 expression
and are associated with poor prognosis [37], whereas in
head and neck cancer, flotillin-2 overexpression shows a
strong predictive value for the development of metasta-
ses [36]. In breast cancer, increased flotillin-2 levels cor-
relate with reduced patient survival [29].
Due to the above findings and importance of flotillins
for signaling pathways that regulate cell proliferation, it
has been suggested that flotillins may represent promis-
ing targets for cancer therapy. In line with this, acute flo-
tillin depletion impairs signaling and cell proliferation in
some cancer cells, as shown by us and others [16,29,35],
and flotillin deficiency in a mouse breast cancer model re-
duces the formation of metastases [33]. We here show
that stable knockdown of flotillin-1 in the human breast
adenocarcinoma MCF7 cell line results in upregulation of
EGFR mRNA and protein expression and hyperactivation
of MAPK signaling, whereas ErbB2 and ErbB3 expression
are not affected. We provide evidence that the overexpres-
sion of EGFR in MCF7 cells is dependent on the activity
of phosphatidylinositol 3-kinase (PI3K) which carries the
E545K activating mutation in the catalytic subunit of
PI3K. Thus, this study demonstrates that great caution is
required when flotillin expression is targeted in cancer
cells, as unexpected effects may emerge that even facilitate
cancer cell growth and proliferation.
Methods
Antibodies
Rabbit polyclonal antibody against EGFR (D38B1) and
antibody against phospho-EGFR (pTyr1173), AKT, AKT2
(5B5), phospho-AKT (Ser473), MEK1/2, phospho-MEK1/
2 (Ser217/221) and phospho-Raf1 (pSer338) were pur-
chased from Cell Signaling Technology (Danvers, MA,
USA). Rabbit polyclonal antibodies against ERK2 and
Raf-1 and mouse monoclonal antibodies against phospho-
ERK1/2 (Tyr204), LAMP3/CD63 and EGFR (528) were
Table 1 Primers used in this study
Primer Name Sequence
Rpl13a forward 50-CCTGGAGGAGAAGAGGAAAGAGA-30
Rpl13a reverse 50-TTGAGGACCTCTGTGTATTTGTCAA-30
GAPDH forward 50-CATCTTCCAGGAGCGAGATCCC-30
GAPDH reverse 50-CCAGCCTTCTCCATGGTGGT-30
EGFR-A for 50-AAAGAAAGTTTGCCAAGGCACGA-30
EGFR-A rev 50-CTCCACTGTGTTGAGGGCAATGAG-30
EGFR-B for 50-ATCTGCCTCACCTCCACCGT-30
EGFR-B rev 50-CCAAGTAGTTCATGCCCTTTGCGA-30
Cyclin D1 for 50-TCGTGGCCTCTAAGATGAAGGA-30
Cyclin D1 rev 50-CAGCTCCATTTGCAGCAGCTC-30
Flot1-RNAi-res-A for 50-CACACTGACCCTAAACGTCAAGAGCGA
GAAGGTTT ACACTC-30
Flot1-RNAi-res-A rev 50-GAGTGTAAACCTTCTCGCTCTTGACGTTT
AGGGTCA GTGTG-30
Flot1-RNAi-res-B for 50-CTAGCCGAGGCCGAGAAATCCCAGCTA
ATTATGCA GGC-30
Flot1-RNAi-res-B rev 50-GCCTGCATAATTAGCTGGGATTTCTCGG
CCTCGGCT AG-30
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CA, USA). A mouse monoclonal antibody against
GAPDH was from Abcam. Rabbit polyclonal anti-
bodies against flotillin-1 and flotillin-2 were purchased
from Sigma-Aldrich (Taufkirchen, Germany). For de-
tection of E-cadherin, flotillin-1 or flotillin-2 in West-
ern blots, monoclonal mouse antibodies from BD
Transduction Laboratories (Franklin Lakes, NJ, USA)
were used. For enhancing the GFP signal in rescue ex-
periments we used a polyclonal GFP antibody (Clon-
tech Laboratories, Inc., Takara Bio Group). The primary
antibodies used for immunofluorescence were detected
with a Cy3 conjugated goat anti-mouse antibody (Jackson
ImmunoResearch, West Grove, PA, USA) and with an
Alexa Fluor 488 donkey anti-rabbit antibody (Life Tech-
nologies, Karlsruhe, Germany). The primary antibodies
used for Western blotting were detected with a HRP con-
jugated goat anti-mouse or goat anti-rabbit antibody
(Dako, Glostrup, Denmark).
Cell culture and RNA interference
MCF7 cells were cultured in Dulbecco’s Modified Eagle’s
Medium (DMEM high glucose) supplemented with 10%
fetal bovine serum (Life technologies) and 1% penicillin/
streptomycin at 37°C under 5% CO2. Expression of
flotillin-1 and flotillin-2 was stably knocked down in
MCF7 cells using the Mission Lentiviral shRNA system
(Sigma-Aldrich), with two viruses each targeting differ-
ent sequences in human flotillin-1 or flotillin-2. The
control cells were established using an shRNA that
does not target any human gene. Establishment of the
stable knockdown cell lines was done as described pre-
viously for HeLa cells [17].
Plasmids, transfection and generation of stable MCF7 cells
Full length human flotillin-1-pEGFP was a kind gift of
Duncan Browman. For the generation of RNAi resistant
flotillin-1-pEGFP constructs, mutagenesis was carried
out with the QuikChange Site-Directed Mutagenesis
Kit (Stratagene, La Jolla, USA) according to the manu-
facturer’s protocol using the primers listed in Table 1.
Rat-flotillin-2-EGFP [26], which is resistant against the
human shRNA sequences due to natural silent substi-
tutions in the rat sequence, was used for flotillin-2 res-
cue experiments. For stable plasmid transfections of
MCF7 knockdown cells, we used the Neon electropor-
ation system (Life Technologies) with following set-
tings: 400,000 cells, 1230 V, 20 mV, 5 μg plasmid DNA.
After transfection, stable clones were selected for six
weeks with G418 (500 μg/ml).
Growth factor and inhibitor treatment
MCF7 cells were serum-starved for 16 hours before
treatment with 100 ng/ml epidermal growth factor (EGF,Sigma-Aldrich) for the indicated times. For the inhibition
of EGFR tyrosine kinase, MCF7 cells were serum-starved
for 20 hours and treated with 1 μM AG9 (control) or
1 μM PD153035 (EGFR kinase inhibitor) for 5 min at
37°C prior to stimulation with 100 ng/ml EGF for
10 min at 37°C. For PI3 kinase inhibition, MCF7 cells
were treated in normal growth medium with 20 μM
Ly294002 (PI3K inhibitor) or DMSO (control) for
24 hours at 37°C.
Immunofluorescence
Cells were cultured on coverslips and fixed with methanol
at −20°C. The cells were labeled with primary antibodies
and Cy3 and/or Alexa Fluor488 conjugated secondary
antibodies and then embedded in Gel Mount (Biomeda,
Foster City, USA) supplemented with 1,4-diazadicyclo
(2,2,2)-octane (50 mg/ml; Fluka, Neu-Ulm, Germany).
The samples were analyzed with a Zeiss LSM710 Confocal
Laser Scanning Microscope (Carl Zeiss, Jena, Germany).
Cell lysis, gel electrophoresis and Western blot
Cell pellets were lysed in lysis buffer (50 mM Tris–HCl
pH 7.4, 150 mM NaCl, 2 mM EDTA, 1% Nonidet P-40)
supplemented with protease inhibitor cocktail (Sigma-
Aldrich), 1 mM sodium fluoride and 1 mM sodium
orthovanadate (for EGF stimulation) and lysates were
cleared by centrifugation. Protein concentration was
measured with the Bio-Rad protein assay reagent
(Biorad, Munich, Germany). Equal protein amounts of
the lysates were analyzed by SDS-PAGE and Western
blot.
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RNA was isolated using the NucleoSpin RNA purifica-
tion kit (Macherey-Nagel, Düren, Germany). Of each
MCF7 clone, 3 μg of RNA was reverse-transcribed with
2 μM oligo(dT) primers, 2 μM random primers (NEB)
and 200 units Moloney murine leukemia virus reverse
transcriptase (ProtoScript II reverse transcriptase, NEB)
in a total volume of 20 μl. Real-time PCRs (CFX connect
96 – QPCR-System, Bio-Rad) were performed in dupli-
cates with 0.5 μl of 5-fold diluted cDNA in a 13 μl re-
action using SensiFAST SYBR NoROX-Kit (Bioline,
Luckenwalde, Germany). The annealing temperature
was 66°C for all PCR reactions. Primers were designed
to be specific for cDNA with PerlPrimer (Table 1). The
mean of the reference genes Rpl13a and GAPDH was
used for normalization.
Cell viability assay
MCF-7 cells were seeded in 12-well plates at an initial
density of 5 × 105 cells/well. The following day, they
were treated with 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl
tetrazolium bromide (0.5 mg/ml, Sigma-Aldrich) at 37°C for
2–4 hours. Thereafter, 600 μl DMSO was added to the cells
to dissolve the formazan crystals, and the absorbance was
measured at 570 nm, with reference at 690 nm.
Statistical analysis
Unless otherwise stated, all experiments were performed
at least three times. For the statistical analysis, Western
blot bands of proteins were quantified by scanning
densitometry using Quantity One Soft-ware (Bio-Rad)
and normalized to GAPDH or as indicated. Phosphory-
lated proteins were normalized against the total amount of
the respective protein. Data are shown as the mean ± SD.
Statistical comparisons between groups were made using
one-way or two-way analysis of variance (ANOVA) as
appropriate using GraphPad Prism 6 software. Values of
p < 0.05 were considered significant (*), whereas values
of p < 0.01 and p < 0.001 were defined very significant
(**) and highly significant (***), respectively.
Electronic manipulation of images
The images shown have in some cases as a whole been
subjected to contrast or brightness adjustments. No
other manipulations have been performed unless other-
wise stated.
Results
Generation of stable knockdown MCF7 cell lines for flotillins
Flotillins have been previously connected to various can-
cers, including breast cancer. To study the function of
flotillins in breast cancer cells, we generated human
MCF7 cell lines in which flotillin-1 or flotillin-2 expression
was stably knocked down by means of lentivirus mediatedshort hairpin RNAs (shRNAs). The knockdown cell lines
showed a profound reduction of the respective flotillin pro-
tein (85-95%), as detected by means of Western blot
(Figure 1A-B). Although in most cell lines we have
studied so far, flotillin-2 knockdown results in destabilization
and depletion of flotillin-1 protein as well, we detected sub-
stantial amounts of flotillin-1 (>40% of the control) in
flotillin-2 knockdown cells. However, flotillin-2 amount was
unchanged in in flotillin-1 knockdown cells. These results
were further corroborated by means of immunostaining
(Figure 1C) which showed results consistent with the
Western blot analysis. Staining for the other two flotil-
lin knockdown cell lines are shown in Additional file 1A.
Consistent with the findings of Lin et al. in MCF7 cells,
flotillin knockdown resulted in a mild impairment of via-
bility (Additional file 1B).
Expression of the EGF receptor is increased in flotillin-1
knockdown cells
Breast cancer cells frequently exhibit an increased amount
of the HER2/ErbB2 receptor protein that belongs to the
EGFR receptor family. Recent data have shown that in
gastric tumors, flotillin-2 expression correlates with
HER2/ErbB2 levels and flotillin-2 knockdown in a gas-
tric cancer cell line results in reduced HER2 expression
[37]. Our recent data suggest that EGFR signaling is
impaired upon flotillin-1 knockdown in HeLa cells
[16]. Thus, we measured the expression of EGFR,
ErbB2 and ErbB3 in our stable knockdown MCF7 cells
(Figure 2). Surprisingly, the expression of EGFR was
significantly increased in flotillin-1 knockdown cells
(Figure 2A and B), whereas neither ErbB2 (Figure 2C)
nor ErbB3 (Figure 2D) exhibited an altered expression.
Flotillin-2 knockdown cells showed a mildly but not
significantly increased EGFR expression, consistent
with the partial reduction of flotillin-1 in these cells.
The increase in EGFR expression was also clearly de-
tectable by means of immunofluorescence (Figure 2E).
Although EGFR was virtually undetectable in control
shRNA MCF7 cells by antibody staining, we readily ob-
served a plasma membrane associated staining in all
flotillin knockdown cells, consistent with the increased
expression (Figure 2E).
In breast cancer, EGFR overexpression is mainly
based on transcriptional regulation [38]. To study if
the increased EGFR expression is mediated by tran-
scriptional upregulation or reduced protein turnover,
we measured the mRNA of EGFR by means of quanti-
tative real-time PCR with two different primer pairs
(Figure 2F). In line with the higher protein amount,
EGFR mRNA was significantly increased in flotillin-1
knockdown cells, whereas flotillin-2 knockdown cells
exhibited a tendency to a higher EGFR mRNA, which
did not reach significance (Figure 2F).
Figure 1 Characterization of MCF7 cells stably depleted of flotillin-1 and flotillin-2. (A) Expression of flotillins in MCF7 cells depleted of
flotillin-1 (sh-F1-A/B) or flotillin-2 (sh-F2-A/B). GAPDH was detected to show equal loading. (B) Densitometric quantification of flotillin-1 and
flotillin-2. The signals were normalized to GAPDH. Bars represent the mean ± SD of three independent experiments. Statistical analysis using
one-way ANOVA. ***, p < 0.001. (C) Staining of endogenous flotillin-1 and flotillin-2 in MCF7 cells depleted of flotillin-1 (sh-F1-A) or flotillin-2
(sh-F2-A). Scale bar: 20 μm.
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flotillin-1 knockdown cells
Flotillin-1 has been suggested to be involved in the endo-
cytosis of various proteins [19,23,39]. Since inhibition of
EGFR endocytosis might affect its half-life and thus
contribute to the increased amount seen in flotillin-1
knockdown cells, we checked by means of immunofluor-
escence staining if EGFR endocytosis was impaired. These
experiments were only performed in flotillin-1 knockdown
cells, as EGFR staining was not visible in the control cells
due to its low expression level (Figure 2E). Rapid endo-
cytosis of EGFR was found to occur despite flotillin-1 de-
pletion. Already after 5 min of EGF stimulation, EGFR
was detected in perinuclear vesicular structures where it
colocalized with LAMP3/CD63, which is a marker for
multivesicular bodies and late endosomes. The amount of
the endocytosed receptor increased upon 30 min of stimu-
lation. However, the staining pattern was slightly different
from that observed after 5 min of EGF, and EGFR becameless concentrated in the perinuclear region but still colo-
calized with LAMP3 in more peripheral vesicular struc-
tures (Figure 3). Thus, flotillin-1 depletion does not
appear to inhibit EGFR endocytosis from the plasma
membrane, consistent with our prior findings in HeLa
cells [16].
EGFR expression can be reduced upon flotillin re-
expression
To show a direct causative connection between flotillin
depletion and EGFR expression levels, we performed
rescue experiments by stably re-expressing EGFP-tagged
flotillins in the knockdown cells. For this purpose, rat
flotillin-2-EGFP [26] which is identical to the human
one at protein level but distinct at the DNA level, result-
ing in resistance against the shRNAs, was used. For
flotillin-1, we used a human flotillin-1-EGFP construct
that was converted resistant towards the shRNAs by tar-
geted silent mutations. The increased EGFR amount in
Figure 2 Expression of the epidermal growth factor receptor family members in MCF7 cells depleted of flotillin-1 or flotillin-2.
Expression of the epidermal growth factor receptor family members EGFR, ErbB2 and ErbB3 in MCF7 cells depleted of flotillin-1 (sh-F1-A/B) or
flotillin-2 (sh-F2-A/B). (A) Western blot using specific antibodies. GAPDH was detected to show equal loading. (B-D) Densitometric quantification.
The signals were normalized to GAPDH. Bars represent the mean ± SD of three independent experiments. Statistical analysis using one-way
ANOVA. *, p < 0.05; **, p < 0.01. (E) Staining of endogenous EGFR in MCF7 cells depleted of flotillin-1 (sh-F1-A/B) or flotillin-2 (sh-F2-A/B). Scale bar:
20 μm. (F) Quantitative real-time PCR analysis showing the relative mRNA level of EGFR in MCF7 control and flotillin-1 (sh-F1-A/B) or flotillin-2
(sh-F2-A/B) knockdown cells using two different primer pairs. The expression was normalized to GAPDH and Rpl13a. Bars represent the
mean ± SD of three independent experiments. Statistical analysis using one-way ANOVA. *, p < 0.05; **, p < 0.01; ***, p < 0.001.
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expression of the respective flotillin in these cells (Figure 4).
Since not all of the cells shown express the rescueconstructs, they provide an internal control, and the reduc-
tion of EGFR amount was only seen in cells re-expressing
flotillins. Thus, these data show that the increased EGFR
Figure 3 EGFR endocytosis is not impaired upon flotillin-1
depletion. Staining of endogenous EGFR (green) and LAMP3
(red) after EGF-stimulation (100 ng/ml) for 5 and 30 minutes in
MCF7 cells depleted of flotillin-1 (sh-F1-B). Scale bar: 20 μm.
Figure 4 Ectopic expression of flotillins normalizes EGFR
expression in stable MCF7 flotillin knockdown cells. MCF7
control and flotillin-1 (sh-F1-A/B) or flotillin-2 (sh-F2-B) knockdown
cells stably transfected with flotillin-2 (Flot2-EGFP) and flotillin-1
(Flot1-resA/-resB) constructs were grown subconfluent on coverslips,
fixed and stained with antibodies against endogenous EGFR (red)
and GFP (green). EGFP was stained with antibodies to enhance the
signal as the expression levels in the stable cells were kept low in
order not to exceed that of endogenous flotillins in normal cells.
Nuclei were stained with DAPI. Scale bar: 10 μm.
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consequence of flotillin depletion.
EGFR induced signaling towards MAP kinases is increased
in flotillin knockdown cells
To show that the increase in EGFR amount also culmi-
nates in an increased downstream signaling response, we
stimulated the cells with EGF for 10 and 30 min after
overnight serum starvation. The activation of the MAP
kinase cascade was detected by Western blot by means
of antibodies specific to the activated kinases of this
pathway. Figure 5 shows the respective blots (Figure 5A)
together with the quantification data (Figure 5B-G).
The data for the further two cell lines are shown in
Additional file 2. Consistent with the above data, the
flotillin-1 knockdown cells showed a significantly in-
creased EGFR expression (Figure 5B). The phosphoryl-
ation of EGFR in Tyr1173 (pY1173), when normalized to
GAPDH, showed a significant increase upon 10 min of
stimulation in all four knockdown cell lines (Figure 5C).
When the phosphorylation was correlated to the amount
of EGFR, these values barely reached significance
(Figure 5D), implicating that the receptors are acti-
vated to a normal degree, and the increased pY1173 is
due to increased receptor amount. Phosphorylation of
both MEK1/2 and ERK1/2 were also significantly in-
creased after 10 min EGF in flotillin-1 knockdown
cell lines (Figure 5E-F, Additional file 2), whereas the
amount of total MEK and ERK was not changed (data
not shown). Phosphorylation of Raf-1 at Ser338 wassignificantly increased in one of the flotillin-1 knock-
down lines (Figure 5G). Consistent with the upregula-
tion of MAP kinase signaling, we found that the
mRNA for the downstream target cyclin D was in-
creased in flotillin-1 knockdown cells (Additional file
1C). We also detected the activation of protein kinase
B/AKT in our knockdown cells (Figure 5A). Although
the signal for phospho-Ser473 of AKT tended to be
higher in flotillin knockdown cells, it only reached
significance at 10 min EGF stimulation in one of the
flotillin-2 knockdown clones (data not shown). This is
most likely due to the fact that MCF7 cells exhibit a
constitutively active PI3 kinase which causes a rela-
tively high basal AKT activity (as seen in the starved
cells in Figure 5A). No change in the amount of total
AKT was detected. Taken together, these data show
that the increased EGFR in flotillin knockdown cells
Figure 5 EGF stimulation of MCF7 cells depleted of flotillin-1 or flotillin-2. (A) Western blot with specific antibodies for pY1173-EGFR, EGFR,
pS473-AKT, AKT, pS338-Raf1, Raf1, pMEK1/2, MEK1/2, pERK1/2, ERK1/2, flotillin-1, flotillin-2 and GAPDH in MCF7 cells depleted of flotillin-1 (sh-F1-B)
or flotillin-2 (sh-F2-A) after EGF-stimulation (100 ng/ml) for 10 and 30 minutes. (B-G) Densitometric quantification of EGFR (B), pY1173-EGFR
(C, D), pMEK1/2 (E), pERK1/2 (F) and pS338-Raf1 (G). The signals for total protein were normalized to GAPDH, phosphorylated proteins to
the corresponding total protein. Bars represent the mean± SD of four independent experiments. Statistical analysis using two-way ANOVA. *, p < 0.05;
**, p < 0.01.
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naling in these cells.
To show that the increased MAPK signaling is due to
EGFR activity and not activation of some other signaling
pathway, we used PD153035, an EGFR kinase inhibitor.
AG9, a non-inhibiting compound was used as a control.
Treatment of the cells with the EGFR inhibitor resulted in
a profound inhibition of both ERK and MEK in EGF stim-
ulated control and flotillin knockdown cells (Figure 6A).
Thus, increased EGFR activity due to its overexpression is
responsible for the increase in MAPK signaling upon flo-
tillin knockdown.
Constitutive activity of PI3K causes EGFR overexpression
upon flotillin knockdown
MCF7 cells exhibit a constitutively active PI3K due to an
E545K activating mutation in the gene encoding for the
catalytic subunit of the PI3K [40]. Since EGFR may be
transcriptionally regulated by PI3K signaling, and we
have not observed a similar upregulation of EGFR in
other cell lines upon flotillin knockdown, we tested if
PI3K inhibition would be sufficient to return EGFR ex-
pression back to the level of control cells. For this,
MCF7 cells were incubated with the PI3K inhibitor
Ly294002 for 24 hours under normal culturing condi-
tions. Inhibition of PI3K was verified by checking AKT
phosphorylation which was almost completely inhibited
upon PI3K inhibitor treatment. Intriguingly, PI3K inhib-
ition resulted in very profound reduction in EGFR levels
in flotillin knockdown cells, whereas it showed a much
lower effect in the control cells (Figure 6B). Quantifica-
tion of the data showed a statistically significant reduc-
tion of EGFR expression upon PI3K inhibition on the
protein level (Figure 6C), whereas the mRNA levels of
EGFR were not significantly reduced (Additional file 3).
These data suggest that upon loss of flotillin-1, the con-
stitutively active PI3K induces the upregulation of EGFR
protein expression in MCF7 cells.
Discussion
We have here used the human breast adenocarcinoma
MCF7 cell line to study the role of flotillins in breast
cancer signaling. Previous studies have suggested that
flotillin ablation might be a promising therapy option in
tumors that exhibit flotillin overexpression [29,33,35,37].
However, we here show that decreased flotillin-1 expres-
sion may result in a paradoxical increase in signaling
due to upregulation of receptors functionally connected
to flotillins. Although most studies on flotillins in cancer
have described an elevated flotillin-2 expression, most of
them did not address flotillin-1 directly [34,36,37] or
found that flotillin-1 expression has no predictive value
in terms of e.g. patient survival [29]. However, flotillins
are strongly interdependent in most cells, as shown byus and others, and even in the flotillin-1 [25] and
flotillin-2 [33,41] knockout mice. Generally, flotillin-1
shows a higher dependency on flotillin-2 expression, so
that flotillin-2 depletion results in profound reduction of
flotillin-1 expression, whereas the effect of flotillin-1 ab-
lation on flotillin-2 levels is less pronounced. Although
it is not clear if flotillin-2 overexpression in tumors also
results in elevated flotillin-1 expression, it would be im-
portant to clarify this issue as flotillins may not be func-
tionally identical.
In the MCF7 cells used in our study, the interdepend-
ency of flotillins appears to be less strong, and considerable
amounts of flotillin-1 (about 40%) are still expressed in the
absence of flotillin-2. Importantly, EGFR overexpression
and increase in signaling correlated with flotillin-1 amount,
and cells depleted of flotillin-2 showed a weaker effect, sug-
gesting that the upregulation of EGFR is directly dependent
on the flotillin-1, but not flotillin-2, amount. These data
are well in agreement with our previous findings showing
that flotillin-1 is involved in EGFR activation and MAPK
signaling [16].
We here discovered a specific upregulation of EGFR
upon flotillin-1 ablation, whereas no change in the levels
of ErbB2 or ErbB3 was detected. EGFR was transcrip-
tionally elevated in the absence of flotillin-1, which is
the main regulatory mechanism of EGFR in most tumors
showing increased EGFR expression [38]. Thus, reduced
degradation alone is unlikely to be responsible for the el-
evated EGFR expression in MCF7 cells, since rapid
endocytosis of EGFR upon EGF stimulation took place
despite flotillin-1 ablation. Unfortunately, it was not pos-
sible to measure EGFR recycling, the elevation of which
might also result in slower receptor degradation and in-
creased amount, as these experiments would require a
comparison to the control cells which show too low ex-
pression of EGFR for direct comparisons.
EGFR expression has been shown to be regulated by
many factors that regulate growth and proliferation. In
breast cancer, EGFR and ErbB2 expression was found to
be under control of the Y-box transcription/translation
factor YB1 which is phosphorylated by Akt [42,43].
However, YB1 has been shown to regulate both EGFR and
ErbB2 expression [42,44]. As we did not observe upregula-
tion of ErbB2 in our flotillin-1 knockdown cells, YB1 is
not very likely to be the cause of EGFR upregulation upon
flotillin-1 knockdown.
Interestingly, previous studies have suggested that ele-
vated flotillin-2 expression in gastric cancers correlates
with ErbB2 levels [37], and flotillins are required to
stabilize ErbB2 in the plasma membrane in SKBR3
breast cancer cells [29]. Depletion of either of the flotillin
proteins resulted in increased endocytosis and degradation
of ErbB2 in these cells, implicating that flotillins regulate
ErbB2 trafficking. Furthermore, flotillins were found to
Figure 6 Upregulation of EGFR in flotillin depleted MCF7 cells is PI3K-dependent. (A) MCF7 control and flotillin-1 (sh-F1-A/B) or flotillin-2
(sh-F2-A/B) knockdown cells were treated with 1 μM EGFR kinase inhibitor (PD153035) and 1 μM AG9 (control) for 5 minutes prior to stimulation
with EGF (100 ng/ml). Western blot with specific antibodies was used to detect pERK1/2, ERK1/2, pMEK1/2, MEK1/2. Loading control: GAPDH.
(B) The cells were treated with 20 μM PI3K inhibitor (Ly294002) and DMSO (control) for 24 hours, followed by detection of EGFR, pS473-AKT
and AKT. Loading control: GAPDH. (C) Densitometric quantification of EGFR. The signals were normalized to GAPDH. Bars represent the
mean ± SD of four independent experiments. Statistical analysis using two-way ANOVA. *, p < 0.05; ***, p < 0.001.
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heat shock protein Hsp90 [29]. However, this appears not
to be the case in MCF7 cells in which the amount of
ErbB2 was not altered upon flotillin depletion. Thus, it is
evident that flotillins exhibit different effects on receptor
trafficking and signaling in breast cancer cells of different
origin. This is not surprising, considering that the cell
lines used are different in terms of their genetic back-
ground and oncogenic mutations that are present in these
cells. For example, according to the Sanger institute COS-
MIC database [40], MCF7 cells exhibit a mutation in the
catalytic subunit of PI3K, whereas SKBR3 cells have a WT
PI3K. However, both cell lines express non-mutated EGFR
and Ras proteins.
Another factor that might affect the results obtained
in various studies is the means of knocking down flotil-
lin expression. For example, Lin et al. [35] described that
flotillin-1 knockdown in MCF7 cells reduces cell viability
and impairs tumorigenicity in MCF7 cells. In contrast to
these data, we here observed elevated MAPK signaling
and increased cyclin D mRNA expression upon flotillin-1
ablation. Furthermore, Lin et al. detected a decreased
AKT phosphorylation and concomitant upregulation of
the forkhead transcription factor Foxo3 which is associ-
ated with decreased cell viability due to upregulation of
apoptotic genes. Although Foxo3 expression was in-
creased in our flotillin-1 knockdown cells (data not
shown), we did not observe any evident impairment of
AKT activation (see Figure 6B), in contrast to Lin et al.
Since AKT activity negatively affects Foxo3 function by
means of a direct phosphorylation, it is plausible that the
increased Foxo3 expression in flotillin knockdown cells is
compensated by the normal AKT activity, thus preventing
Foxo3 from increasing cell death in these cells. Further-
more, PI3K mutations have been shown to promote resist-
ance against apoptosis [11,45] and may thus protect
against increased Foxo3 activity.
There is one significant difference in the experimental
setting as compared to our study. Lin et al. apparently
used a short-term, acute knockdown of flotillins [35],
whereas we have here generated stable flotillin knock-
down MCF7 cell lines. We think that the stable knock-
downs are more representative of the situation in
tumors, as adaptation to flotillin deficiency may result in
compensatory upregulation of signaling proteins, as
shown in the present study, which may not be possible
upon acute knockdown. In line with this, Berger et al.
recently showed that although flotillin-2 deficiency in a
mouse breast cancer model caused a reduced lung metasta-
sis formation, it showed no effect on the growth of primary
tumors [33]. Similarly, we have detected an upregulation of
MAPK signaling and expression of several growth
associated genes in various organs of our flotillin-2
knockout mouse model generated independently of that ofBerger et al. [41]. Thus, long term effects of flotillin abla-
tion may be unpredictable due to compensatory mecha-
nisms, especially in cancer patients.
We have so far only observed the upregulation of
EGFR in MCF7 cells upon stable flotillin depletion.
Since MCF7 cells display a constitutively active PI3K
due to the E545K mutation [40], this prompted us to
study if increased PI3K signaling might be the cause of
EGFR upregulation upon flotillin-1 silencing. Indeed,
EGFR amount was efficiently downregulated upon inhib-
ition of PI3K activity. EGFR is not upregulated e.g. in
human breast epithelial MCF10A, cervix carcinoma
HeLa or human keratinocyte HaCat cells upon stable
flotillin-1 knockdown (our unpublished findings). Ex-
pression of flotillins in these cells lines is not much dif-
ferent from MCF7 cells, but they all exhibit a WT PI3K
[40]. This may suggest that flotillins are required to keep
EGFR amount under control when PI3K is constitutively
activated. This is very likely to occur at least in part by
means of increased activation of an as yet unidentified
transcription factor that regulates EGFR transcription
(see also above) and whose activation also depends on
PI3K signaling. Since activating PI3K mutations that are
oncogenic [11,12] are present in about 25% of breast tu-
mors [7-9], and E545K is one of the most common PI3K
mutations in breast cancer, it will be of uttermost im-
portance to clarify the mutation status of breast cancer
patients before aiming at treatments based on flotillin
ablation.
Conclusions
Due to recent findings showing flotillin overexpression
in various cancer types, flotillins have been suggested to
be promising cancer therapy targets. This idea is also
supported by the fact that genetic ablation of flotillins in
the mouse is well tolerated. However, we here show that
flotillin depletion may result in unexpected hyperactiva-
tion of proliferative signaling pathways, depending on
the molecular signature of the tumor. Thus, before can-
cer therapies based on functional impairment of flotillins
are developed, it will be important to clarify the cross-
talk between flotillins and oncogenic mutations that are
frequently found in specific cancers.
Additional files
Additional file 1: Localization of flotillins in MCF7 cells depleted of
flotillin-1 or flotillin-2. (A) Staining of endogenous flotillin-1 and flotillin-2
in MCF7 cells depleted of flotillin-1 (sh-F1-B) or flotillin-2 (sh-F2-B).
Scale bar: 20 μm. (B) Quantification of the relative viability factor in
MCF7 cells depleted of flotillin-1 (sh-F1-A/B) or flotillin-2 (sh-F2-A/B).
Bars represent the mean ± SD of four independent experiments. Statistical
analysis using one-way ANOVA. **, p < 0.01; ***, p < 0.001. (C) Real-time
PCR data showing the relative cyclin D mRNA level in MCF7 control
and MCF7 flotillin-1 (sh-F1-A/B) or flotillin-2 (sh-F2-A/B) knockdown
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represent the mean ± SD of four independent experiments. Statistical
analysis using one-way ANOVA. **, p < 0.01.
Additional file 2: EGF stimulation of MCF7 cells depleted of flotillin-1
or flotillin-2. (A) Western blot for pY1173-EGFR, EGFR, pS473-AKT, AKT,
pS338-Raf1, Raf1, pMEK1/2, MEK1/2, pERK1/2, ERK1/2, flotillin-1, flotillin-2 and
GAPDH in MCF7 cells depleted of flotillin-1 (sh-F1-A) or flotillin-2 (sh-F2-B)
after EGF stimulation (100 ng/ml) for 10 and 30 min. (B-G) Densitometric
quantification EGFR (B), pY1173-EGFR (C, D), pMEK1/2 (E), pERK1/2 (F) and
pS338-Raf1 (G). The signals of total proteins were normalized to GAPDH,
phosphorylated proteins to the corresponding total protein. Bars represent
the mean ± SD of four independent experiments. Statistical analysis using
two-way ANOVA. *, p < 0.05; **.
Additional file 3: Quantitative real-time PCR analysis of EGFR
expression upon PI3K inhibition. Quantitative real-time PCR analysis
showing the relative mRNA level of EGFR in MCF7 control and flotillin-1
(sh-F1-A/B) or flotillin-2 (sh-F2-A/B) knockdown cells upon PI3 kinase
inhibition. The expression was normalized to GAPDH and Rpl13a.
Bars represent the mean ± SD of four independent experiments.
Statistical analysis using one-way ANOVA.
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